WASHINGTON, July 14 (Reuters) - U.S. drug reviewers have major concerns about effectiveness data supplied by Johnson & Johnson in a bid to win approval for wider use of its Doribax antibiotic, documents released on Monday said.
WASHINGTON, July 14 (Reuters) - U.S. drug reviewers have major concerns about effectiveness data supplied by Johnson & Johnson in a bid to win approval for wider use of its Doribax antibiotic, documents released on Monday said.
